Stability of Expansion Attained with Sel-ligating Bracket System

Background: The Self-ligating system with in-built mechanism to secure the arch wire advocates comfort for the patient and clinician, reduces the chair side time and produces an expansion of the arch. Damon philosophy emphasises on light forces just enough to move teeth. The intra arch expansion is achieved by boarder arch wires, increasing the inter-canine, inter-premolar and inter-molar distance. The stability of the expansion achieved over the retention period determines the success of the treatment. For the clinician, it’s a challenge to assert the merits for the self-ligating brackets as there are limited studies evaluating the stability of the transverse expansion achieved in both adults and adolescents. This literature review focuses on the transverse expansion achieved by self-ligating systems in the long term and to evaluate if there are any variations in the results achieved in adolescents and adults

Toxicity Evaluation and Biocompatibility of Nanostructured Biomaterials

Biomaterials have occupied a prominent place in regenerative procedures to restore human health. Moreover, there is a greater need in understanding, analyzing and establishing their toxicity profile. These, when made into nano-sized constructions called nanostructured biomaterials, their regenerative potential is enhanced, which could influence their toxicity nature. This chapter intends to give comprehensive information on their nanotoxicology pathways at the cellular level, their entry pathways into the human body, and their potential consequences on human health. It clearly explains the cytocompatibility and biocompatibility of various nanostructured biomaterials for potential human health applications like drug delivery and tissue engineering. A detailed overview of various in vitro and in vivo evaluation methods of biocompatibility of nanomaterials are outlined in this chapter that researchers should address as they move forward in developing new systems for the field of regeneration

Diversity analysis of released varieties of Indian cardamom using ISSR markers reveal narrowing genetic base

311-322Elettaria cardamomum Maton the small cardamom of commerce is a monotypic genus in India under the family Zingiberaceae. Genetic diversity studies using inter simple sequence repeat (ISSR) markers were conducted on a total of 13 released varieties of cardamom including selections and hybrids from different research stations in South India along with a popular variety Njallani and a wild relative Aframomum sps as checks. ISSR markers however, revealed relatively high level of genetic redundancy among the tested varieties with the exception of a few. Nonetheless, unweighted pair group method of arithmetic average (UPGMA) based cluster analysis of the similarity matrix differentiated all the varieties tested with the exception of two and segregated the wild relative Aframomum. Considerable reduction of polymorphism percentage was observed on exclusion of Aframomum while studying ISSR polymorphism which could be an indicator of the narrowing genetic base in the released varieties. Morphological data were compiled based on International Plant Genetic Resources Institute (IPGRI) cardamom descriptor and revealed moderate variability among the varieties. The results highlighted the requirement of molecular characterization of unutilized germplasm accessions, related wild species, and exotic relatives using specific molecular markers to help refine breeding efforts and introgression of new alleles for further improvement and enhancement of genetic base of cultivated cardamom

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination

Objective: To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma. Methods: This is a prospective, observational study utilising the RUDYstudy.org platform. Participants reported their second and third COVID-19 vaccination dates. Myeloma patients had an Anti-S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination. Results: 60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti-S antibody levels (<50 IU/mL) doubled during this interval (p = .023) and, in the 47 participants with T-spot data, there was a 25% increase negative T-spot tests (p = .008). Low anti–S antibody levels prior to the third vaccination were predicted by lower Anti-S antibody level and negative T-spot status after the second vaccine. Independent determinants of a negative T-spot included increasing age, previous COVID infection, high CD4 count and lower percentage change in Anti-S antibody levels. Conclusions: Negative T-spot results predict low Anti-S antibody levels (<50 IU/mL) following a second COVID-19 vaccination and a number of biomarkers predict T cell responses in myeloma patients

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication